Global Animal Health Partnering Terms and Agreements 2017 to 2022

$3,995.00
Provides comprehensive understanding and unprecedented access to the animal health agreements entered into by the worlds leading biopharma companies.
Publication date
September 2022
Number of pages
150+
Product type
Research report
Available formats
PDF document
Report edition
4
SKU
CP1015

Welcome to the Global Animal Health Partnering Terms and Agreements 2017 to 2022 report.

 

The report provides a detailed understanding and analysis of how and why companies enter Animal Health partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

 

This report provides details of the latest Animal Health agreements announced in the life sciences since 2017.

 

The report takes the reader through a comprehensive review Animal Health deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Animal Health partnering deals.

 

The report presents financial deal term values for Animal Health deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

 

The middle section of the report explores the leading dealmakers in the Animal Health partnering field; both the leading deal values and most active Animal Health dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

 

One of the key highlights of the report is that over 200 online deal records of actual Animal Health deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

 

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

 

The initial chapters of this report provide an orientation of Animal Health dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Animal Health dealmaking since 2017, including details of headline, upfront, milestone and royalty terms.

 

Chapter 3 provides a review of the leading Animal Health deals since 2017. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Animal Health dealmaking with a brief summary followed by a comprehensive listing of Animal Health deals announded by that company, as well as contract documents, where available.

 

Chapter 5 provides a comprehensive and detailed review of Animal Health partnering deals signed and announced since Jan 2017, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of Animal Health partnering deals signed and announced since Jan 2017. The chapter is organized by specific Animal Health technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

A comprehensive series of appendices is provided organized by Animal Health partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in Animal Health partnering and dealmaking since 2017.

 

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Animal Health technologies and products.

 

Key benefits

 

Global Animal Health Partnering Terms and Agreements 2017 to 2022 provides the reader with the following key benefits:

 

  • In-depth understanding of Animal Health deal trends since 2017
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Animal Health contracts entered into by leading biopharma companies
  • Identify most active Animal Health dealmakers since 2017
  • Insight into terms included in a Animal Health partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

 

Report scope

 

Global Animal Health Partnering Terms and Agreements 2017 to 2022 is intended to provide the reader with an in-depth understanding and access to Animal Health trends and structure of deals entered into by leading companies worldwide.

 

Animal Health Partnering Terms and Agreements includes:

 

  • Trends in Animal Health dealmaking in the biopharma industry since 2017
  • Access to headline, upfront, milestone and royalty data
  • Access to Animal Health contract documents
  • Leading Animal Health deals by value since 2017
  • Most active Animal Health dealmakers since 2017

 

In Global Animal Health Partnering Terms and Agreements 2017 to 2022, the available deals are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target
  • Technology type

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The Global Animal Health Partnering Terms and Agreements 2017 to 2022 report provides comprehensive access to available deals and contract documents for over 200 Animal Health deals.

 

Analyzing actual contract agreements allows assessment of the following:

 

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Global Animal Health Partnering Terms and Agreements 2017 to 2022 provides the reader with the following key benefits:

 

  • In-depth understanding of Animal Health deal trends since 2017
  • Access to headline, upfront, milestone and royalty data
  • Detailed access to actual Animal Health contracts entered into by leading biopharma companies
  • Identify most active Animal Health dealmakers since 2017
  • Insight into terms included in a Animal Health partnering agreement, with real world examples
  • Understand the key deal terms companies have agreed in previous deals           
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Executive Summary

 

Chapter 1 – Introduction

 

Chapter 2 – Trends in Animal Health dealmaking

 

2.1. Introduction

2.2. Animal Health partnering over the years

2.3. Most active Animal Health dealmakers

2.4. Animal Health partnering by deal type

2.5. Animal Health partnering by therapy area

2.6. Animal Health partnering by technology type

2.7. Deal terms for Animal Health partnering

2.7.1 Animal Health partnering headline values

2.7.2 Animal Health deal upfront payments

2.7.3 Animal Health deal milestone payments

2.7.4 Animal Health royalty rates

 

Chapter 3 – Leading Animal Health deals

 

3.1. Introduction

3.2. Top Animal Health deals by value

 

Chapter 4 – Most active Animal Health dealmakers

 

4.1. Introduction

4.2. Most active Animal Health dealmakers

4.3. Most active Animal Health partnering company profiles

 

Chapter 5 – Animal Health contracts dealmaking directory

 

5.1. Introduction

5.2. Animal Health contracts dealmaking directory

 

Chapter 6 – Animal Health dealmaking by technology type

 

Appendices

 

Appendix 1 – Animal Health deals by company A-Z

Appendix 2 – Animal Health deals by stage of development

Appendix 3 – Animal Health deals by deal type

Appendix 4 – Animal Health deals by therapy area

Appendix 5 – Deal type definitions

Appendix 6 – Further reading

 

About Wildwood Ventures

 

Current Partnering

Current Agreements

Recent report titles from Current Partnering

 

Table of figures

 

Figure 1: Animal Health partnering since 2017

Figure 2: Active Animal Health dealmaking activity since 2017

Figure 3: Animal Health partnering by deal type since 2017

Figure 4: Animal Health partnering by disease type since 2017

Figure 5: Animal Health partnering by technology type since 2017

Figure 6: Animal Health deals with a headline value

Figure 7: Animal Health deals with an upfront value

Figure 8: Animal Health deals with a milestone value

Figure 9: Animal Health deals with a royalty rate value

Figure 10: Top Animal Health deals by value since 2017

Figure 11: Most active Animal Health dealmakers since 2017

Pricing options

  • $3,995: single-user
  • $5,745: multi-user
  • $10,995: single site license
  • $17,995: global site license

 

A full explanation of license type definitions can be found here.

 

Our guarantee

 

Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.

 

Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)

 

Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.

 

Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by SagePay.

 

Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

 

Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

AbCellera, Ab E Discovery, Absorption Systems, AdaptVac, Adisseo, ADM, Advanced Animal Diagnostics, Aeronics, AgBiome, Agricultural Research Organization, AKL Research and Development, Algenex, ALK-Abello, ALR Technologies, American Regent, American Veterinary Medical Foundation, Anatara Lifesciences, Angany, AnimalBiome, Animalcare, Animal Clinical Investigation, Animal Life Sciences, Anivive Lifesciences, Ankyra Therapeutics, Apacor, Applied BioSciences, Applied DNA Sciences, Aptimmune Biologics, Aratana Therapeutics, Arcturus Therapeutics, Aridis Pharmaceuticals, Arysta LifeScience, AskAt, Assisi Animal Health, Atomwise, Aurelius Biotherapeutics, Aurinia Pharmaceuticals, Avacta, Avivagen, Basepaws, BASF, Bayer, Bayer Animal Health, Better Choice Company, Better Choice Products, BioChek, BioCopy, BioTecon Diagnostics, Blue Buffalo Company, BodeVet, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Bond Pet Foods, Boragen, Broad Institute, Calysta Energy, CannaSoul Analytics, CannPal Animal Therapeutics, CAPInnoVet, cbdMD, Celsee, Central Institute for Experimental Animals, Centrovet, Ceva Sante Animale, Choom, Colorado State University, Cornerstone Animal Health, Covenant Animal Health Partners, Covetrus, CSA Medical, CSIRO, CURE Pharmaceutical, CVM Ecografía, Daiichi Sankyo, Danish Innovation Fund, Dechra Pharmaceuticals, Deinove, Delf, Department of Defense, Destination Pet, Dovetail Genomics, DSM, Dyadic International, Elanco, ELIAS Animal Health, Emollivet, Envigo, eQcell, Esteve, Ethos Veterinary Health, Eurocine Vaccines, Evah, Evonik Industries, Evotec, Evvivax, Express Scripts, ezyVet, Fatro, FDA Center for Veterinary Medicine, Felix Biotechnology, Food and Drug Administration (FDA), Forte Biotechnology, FSD Pharma, Gencove, Genelux, Genetic Veterinary Sciences, Global Dx, Global Stem Cell Technology, GNA Biosolutions, Gnubiotics Sciences, Greenlight Biosciences, GrowSafe Systems, Heiland, HemPup, Hendrix Genetics, Henry Schein, Heska, Hill's Pet Nutrition, Horizon Discovery, Huvepharma, IdentiGEN, IDEXX Laboratories, Illumina, Immune Therapeutics, Immunomic, Impact NRS, IncellDx, India Globalization Capital, Infinovo Medical, Innovet, Inovalon, Inovet, Inphilco, Insilico Medicine, Institute of Virology and Immunology, Intrexon, Invetx, Jaguar Health, JP Equine Services, Jurox, Kahu Vet Group, Kane Biotech, Kansas State University, Karyopharm Therapeutics, Kemin Industries, Kermode Biotechnologies, Kindred Bio, Konica Minolta, KVP International, Laboratorios Adler, Lacuna Diagnostics, Leiber, LexaGene, LIC Automation, Liiv Organics, Likarda, LineaRx, Lipidor, LiteCure Medical, Livestock Improvement, Loop Genomics, Lumosa Therapeutics, Lytix Biopharma, Magiar Chilena, Marrone Bio Innovations, Mars Petcare, MBF Therapeutics, MBP Solutions, MediCann Handels, MedinCell, MediSapiens, Merck and Co, Merck Animal Health, Midori USA, Miller Veterinary Supply East, Mimi’s Rock, Moleculin Biotech, Mologic, Morris Animal Foundation, MSD Animal Health, MWI Animal Health, MyoKardia, MYOS, NanoSmart Pharmaceuticals, National Institute for Biotechnology in the Negev, Nature-Cide, Neogen, Neptune Technologies & Bioressources, NeuroCycle Therapeutics, NewLeaf Brands, New Ruipeng Group, Nextmune, Nexvet, Nirvana Group, Nong San Viet, Novozymes, Nrgene, Nufarm, Nuritas, NutraMax, NutriQuest, NWO.ai, NXTGEN, Ology Bioservices, Oncology Pharma, Ontera, Orion, Pacific Biosciences, Pacific GeneTech, Pebble Labs, Performance Livestock Analytics, Perrigo, Pestmaster Services, Petco, PetDx, PetIQ, PetLife Pharmaceuticals, Petriage, PharmaCielo, Phibro Animal Health, Phyto Animal Health, PlantForm, Pond Technologies, POSCO International, Poultry Sense, Precigen, Primordial Genetics, ProBioGen, PulseVet, Purdue Research Foundation, Purdue University, PureKana, Purina, Qorvo Biotechnologies, Quantified Ag, Redbarn Pet Products, Regen BioPharma, Regeneron Pharmaceuticals, RegenLab, Rejuvenate Bio, Reliance Animal Health Partners, Revive & Restore, Revo Squared, Riemser, Ripe Technology, Sanofi, Science Biotech, Scil Animal Care, Seed Mena, Sharp Edge Labs, Simulations Plus, Skyline Vet Pharma, Sonoma Pharmaceuticals, Southwest Research Institute, STEM Animal Health, Stonehaven Incubate, Structured Monitoring Products, Sumitomo Dainippon Pharma, Syngenta, Synthetic Genomics, SynWorld Technologies, Takis Biotech, Techcyte, Technology Acceleration Partners, TeleVet, Tetra Bio-Pharma, Torigen Pharmaceuticals, Toronto Innovation Acceleration Partners, Trans Ova Genetics, Trianni, TriRx Pharmaceutical Services, Tufts University, Twist Bioscience, UNION Therapeutics, University of California, Davis, University of Connecticut, University of Illinois Urbana-Champaign, University of Liverpool, University of Queensland, University of Vermont, University of Zurich, US Department of Agriculture, Valent Biosciences, VCA Antech, VCP, Verios Agro, VERT, Vet-Allergy, Veterinary Pharmacology Research Foundation, Vetigenics, VetNOW, Vetoquinol, Vets First Choice, Victor Medical, Vida Concepts, Vimian Group, Virbac, Vita Bee Health, VitalPet, Vitanova Biomedical, Vium, Vivaldis, VolitionRX, Vuja De Sciences, Vytelle, Wanda Fish Technologies, Wedgewood Pharmacy, Wildlife Pharmaceuticals, World Pet Care Products Company, Zander Therapeutics, Zenoaq, Zivo Bioscience, Zoetis, Zomedica, Zydus Cadila, Zymeworks

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!